Drug developer AEON Biopharma files for a $75 million IPO

Ref: Renaissance Capital
  • AEON Biopharma filed with the US Securities and Exchange Commission on Friday to raise up to $75 million in an initial public offering, Renaissance Capital reported.

  • The company is developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. 

  • AEON’s IND application for ABP-450 as a preventative treatment for migraine was accepted by the FDA in the fourth quarter of 2020. The company plans to announce topline data in the second half of 2022.

  • Its IND application for ABP-450 as a treatment for cervical dystonia was accepted by the FDA in the third quarter of 2020. Topline data is expected in early 2022.

  •